PTSD - Post Traumatic Stress Disorder Clinical Trial
Official title:
Low-Frequency Versus High-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in Posttraumatic Stress Disorder
NCT number | NCT02369614 |
Other study ID # | NMCSD.2014.0061 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2014 |
Est. completion date | March 2019 |
Verified date | March 2019 |
Source | United States Naval Medical Center, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized placebo/sham controlled, double-blind study investigating the efficacy of high- and low-frequency rTMS applied to the right DLPFC at either 1 Hz, 10 Hz, or sham rTMS as compared to an OASIS treatment as usual group for the treatment of PTSD symptoms.
Status | Terminated |
Enrollment | 30 |
Est. completion date | March 2019 |
Est. primary completion date | March 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: Participant in the OASIS program Willing and able to give informed consent Diagnosis of Post-Traumatic Stress Disorder as determined by the CAPS CAPS score of at least 50 Males or females between 18-65 years of age Exclusion Criteria: Current primary Axis I disorder including Schizophrenia, Bipolar Disorder type I, Active Substance use Patients with severe or unstable medical conditions, which in the opinion of the investigator would interfere with their progress or safety ECT treatment within the last 30 days Patients with neurological disorder leading to increased intracranial pressure Participation in other interventional treatment protocols (participants of monitoring/observational studies can be included) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
United States Naval Medical Center, San Diego |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Clinician Administered PSTD Scale (CAPS) score from Baseline to week 4 | Clinician Administered PSTD Scale (CAPS) | Baseline and Week 4 |